Anumana Receives the US FDA’s Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction
Shots:
- The company received the US FDA clearance for ECG-AI LEF, its new artificial intelligence (AI) model that identifies signs of low ejection fraction (LEF) in patients at risk of heart failure. The ECG-AI LEF algorithm was developed as part of a collaboration with the Mayo Clinic
- The (EAGLE) study conducted by Mayo Clinic showed that the AI algorithm improved diagnosis of low EF by 31% over SoC without increasing the overall rate of echocardiogram usage
- The AI model was validated in a clinical trial involving 16000 patients and showed a sensitivity of 84.5% and specificity of 83.6%. ECG-AI LEF achieved an AUROC7 of 0.932 demonstrating an ability to differentiate b/w LEF and EF >40%
Ref: Businesswire | Image: Pfizer
Related News:- Pfizer Entered into a Multi-Year Agreement with Anumana to Develop AI Algorithm for the Detection of Cardiac Amyloidosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
